Meral Beksac, MD, Ankara University, Ankara, Turkey, provides an insight into new trends in multiple myeloma as seen in this year’s American Society of Hematology (ASH) annual meeting, including the strides taken in biological therapies and new molecules that can direct immunologic responses to cancer. Furthermore, Dr Beksac highlights the importance of sequential therapies in multiple myeloma and approaches that are currently being evaluated. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.